Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Borut Kobal) .

1 - 10 / 39
Na začetekNa prejšnjo stran1234Na naslednjo stranNa konec
1.
The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
Erik Škof, Sebastjan Merlo, Gašper Pilko, Borut Kobal, 2016, izvirni znanstveni članek

Povzetek: Primary treatment of patients with advanced epithelial ovarian cancer consists of chemotherapy either before (neoadjuvant chemotherapy, NACT) or after primary surgery (adjuvant chemotherapy). The goal of primary treatment is no residual disease after surgery (R0 resection) what is associated with an improvement in survival of patients. There is, however, no evidence of survival benefits in patients with R0 resections after prior NACT. Methods. We retrospectively reviewed the records of patients who were treated with diagnosis of epithelial ovarian cancer at Institute of Oncology Ljubljana in the years 2005%2007. The differences in the rates of R0 resections, progression free survival (PFS), overall survival (OS) and in five-year and eight-year survival rates between patients treated with NACT and patients who had primary surgery were compared. Results. Overall 160 patients had stage IIIC epithelial ovarian cancer. Eighty patients had NACT and eighty patients had primary surgery. Patients in NACT group had higher rates of R0 resection (42% vs. 20%; p = 0.011) than patients after primary surgery. PFS was 14.1 months in NACT group and 17.7 months after primary surgery (p = 0.213). OS was 24.8 months in NACT group and 31.6 months after primary surgery (p = 0.012). In patients with R0 resections five-year and eight-year survival rates were 20.6% and 17.6% in NACT group compared to 62.5% and 62.5% after primary surgery (p < 0.0001), respectively. Conclusions. Despite higher rates of R0 resections achieved by NACT, survival of patients treated with NACT was inferior to survival of patients who underwent primary surgery. NACT should only be offered to patients with advanced epithelial cancer who are not candidates for primary surgery.
Ključne besede: ovarian cancer, advanced ovarian cancer, neoadjuvant chemotherapy, primary surgery
Objavljeno v DiRROS: 30.04.2024; Ogledov: 162; Prenosov: 39
.pdf Celotno besedilo (597,52 KB)

2.
Circulating serum sVCAM-1 concentration inadvanced ovarian cancer patients : correlation with concentration in ascites
Marina Jakimovska, Katarina Černe, Ivan Verdenik, Borut Kobal, 2014, izvirni znanstveni članek

Povzetek: Background. Vascular cell adhesion molecule-1 (VCAM-1) is associated with ovarian cancer progression but theorigin of its soluble form (sVCAM-1) in serum is not well investigated. The purpose of this study was to elucidate whetherthe concentration of sVCAM-1 in serum correlates with the concentration in ascites, that represents local tumour environment,and with systemic inflammation, various clinicopathological characteristics, and patient outcome.Patients and methods. Thirty-six patients with advanced ovarian cancer were included in the study. Serum forsVCAM-1 analysis was obtained prior to surgery. Ascites samples were collected at the beginning of the operation.Clinical data were collected from patients medical records. sVCAM-1 in samples was analysed by flow cytometricbead-based assay. The mean follow-up period was 11 months (range 0-23) from the time of surgery.Results. Serum sVCAM-1 concentrations are positively correlated to ascites sVCAM-1 concentrations. There was aweakly positive correlation of serum sVCAM-1 with tumour size and no correlation with inflammatory tumour markers,FIGO stage or grade. Higher concentrations of sVCAM-1 were associated with poor disease outcome (death fromovarian cancer) in almost all cases before chemotherapy was started.Conclusion. This is the first study demonstrating that serum concentrations of sVCAM-1 in advanced ovarian cancerpatients correlate with sVCAM-1 concentrations in ascites, thus expressing the biologic potential of malignant diseaseto metastasis, rather than systemic inflammation. Higher serum and ascites sVCAM-1 concentrations might have predictivepotential for different biologic behaviour.
Objavljeno v DiRROS: 16.04.2024; Ogledov: 318; Prenosov: 217
.pdf Celotno besedilo (491,78 KB)

3.
Uporaba energetskih inštrumentov pri kirurškem zdravljenju raka jajčnikov
Borut Kobal, 2023, objavljeni znanstveni prispevek na konferenci

Ključne besede: rak jajčnikov, kirurško zdravljenje, ginekološki raki
Objavljeno v DiRROS: 23.11.2023; Ogledov: 245; Prenosov: 115
.pdf Celotno besedilo (196,71 KB)
Gradivo ima več datotek! Več...

4.
Vloga ekstraabdominalne kirurgije pri napredovalem raku jajčnika
Borut Kobal, 2021, objavljeni znanstveni prispevek na konferenci (vabljeno predavanje)

Ključne besede: ginekološki raki, rak jajčnikov, onkološko zdravljenje
Objavljeno v DiRROS: 30.03.2022; Ogledov: 523; Prenosov: 248
.pdf Celotno besedilo (177,44 KB)
Gradivo ima več datotek! Več...

5.
6.
7.
8.
9.
10.
Iskanje izvedeno v 0.35 sek.
Na vrh